Simulations Plus Releases GastroPlus® Version 9.8.3

Keywords: additional dosage routes, GastroPlus 9.8.3, in silico, NAFL, NASH, PBBM modeling, PBPK model, qsp, QST
Software: GastroPlus®
Division: PBPK

Simulations Plus Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of version 9.8.3 of its flagship physiologically based biopharmaceutics (PBBM) / pharmacokinetics (PBPK) modeling platform, GastroPlus®.

Key enhancements include:

  • Improved reporting templates for the Monolix™ software to support the statistical analysis of virtual PBPK population results
  • New validated nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) disease populations with options to inform the NAFLDsym® software
  • New validated swine PBPK model to drive pharmaceutical and veterinary medicine research
  • New enzyme and transporter expression levels across species to expand the virtual population databases
  • Flexible handling of dose regimens to allow for administration of any Additional Dosage Routes model during simulations

Dr. Haiying Zhou, director of Simulation Technologies, said: “Our goals with this release of GastroPlus were twofold: to advance the ways in which our software programs communicate with each other across the Simulations Plus universe and to provide the flexibility our users require to simulate the scenarios they need. We succeeded in this effort through our close collaborations with our partners in industry, academia, and government agencies and by working in harmony with the product development teams of our company.”

“We continue to push the boundaries for how PBBM/PBPK modeling should be integrated with machine learning, quantitative systems pharmacology/toxicology (QSP/QST), and population PK/PD approaches,” added Daniel O’Connor, director of Business Development. “Our leadership in this space is reflected through the growing number of companies applying GastroPlus to support candidate selection, first-in-human dose selection, formulation optimization, drug-drug interaction assessments, and more – all within a single software environment. We are excited to release this new version to our user community and continue to support and educate researchers worldwide by providing the best and most innovative science.”